A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of
stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients
with cancer.

- The phase 1 study will evaluate the feasibility and safety of delivering SMART in
patients with cancer.

- Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and
improvement in patient reported outcome measures

Inclusion Criteria:

- Participants must have a confirmed malignancy requiring stereotactic body radiation
therapy. See specific disease site cohorts for more details.

- Tumor size ≤ 7cm

- Age 18 years of older.

- ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)

- Ability to understand and the willingness to sign a written informed consent document.

- Specific eligibility requirements for each disease site with be covered in each
specific cohort.

Exclusion Criteria:

- Specific exclusion requirements for each disease site with be covered in each specific
cohort

- History of allergic reactions attributed to gadolinium-based IV contrast.

-- Note: If a patient will not receive contrast, this is not applicable

- Pregnant women are excluded from this study.

- Severe claustrophobia or anxiety

- Participants who cannot undergo an MRI